Notice of NHLBI Participation in PA-19-112 "Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)"
Notice NOT-HL-19-674 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 17, 2019 Category: Research Source Type: funding
NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
Funding Opportunity PAR-19-155 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to support studies that are scientifically essential, yet also sufficient, for investigators to make definitive decisions that inform the final designs of important Phase II and beyondclinical trials within NHLBI's mission; that is, clinical trials with the primary intent of testing the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and treatment of heart, lung, blood, and sleep disorders. This mechanism may be used to test the feasibility of novel and ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 8, 2019 Category: Research Source Type: funding
U.S.-China Program for Biomedical Collaborative Research (R01 Clinical Trial Optional)
Funding Opportunity RFA-CA-19-009 from the NIH Guide for Grants and Contracts. The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Chinese researchers in the areas of cancer, environmental health, heart disease, blood disorders, diseases of the eye and visual system, mental health, and neurological disorders. Partnering U.S. and Chinese investigators must work jointly to submit identical applications to NIH and National Natural Science Foundation of China (NSFC), respective...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 2, 2019 Category: Research Source Type: funding
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)
Funding Opportunity PA-19-112 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applica...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 17, 2018 Category: Research Source Type: funding
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional)
Funding Opportunity PA-19-111 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applica...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 17, 2018 Category: Research Source Type: funding
Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
Funding Opportunity PAS-19-105 from the NIH Guide for Grants and Contracts. The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonma...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 17, 2018 Category: Research Source Type: funding
Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the le...
Source: NIDDK Funding Opportunities - December 17, 2018 Category: Endocrinology Source Type: funding
Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the l?...
Source: NIDDK Funding Opportunities - December 17, 2018 Category: Endocrinology Source Type: funding
Notice of Changes to RFA-AG-19-020 "Clinical Trial on Effects of Statins in Older Adults without Clinical Cardiovascular Disease (U19 Clinical Trial Required)"
Notice NOT-AG-18-038 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 8, 2018 Category: Research Source Type: funding
New Research Directions that Advance the NHLBI Strategic Vision Normal Biology (R21 - Clinical Trial Not Allowed)
Funding Opportunity PA-19-049 from the NIH Guide for Grants and Contracts. The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided bya detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. ?Areas of?r?e?s?e?a?r?c?h? ?i?n?t?e?r?e?s?t?include? ?s?t?u?d?i?e?s? ?o?f? ?f?u?n?d?a?m?e?n?t?a?l? ?p?r?o?c?e?s?s?e?s? ?t?h?a?t?explain resilience the capability of some individuals to maintain or restore normal function despite aging or exposurethat causes disease...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 1, 2018 Category: Research Source Type: funding
NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-19-048 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. Successful applicants will provide biospecimens for whole genome sequencing or other omics assays. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public database such as dbGaP. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 1, 2018 Category: Research Source Type: funding
Request for Information (RFI): Understanding the Health of Women and the Role of Sex/Gender in Mechanisms of Heart, Lung, Blood, and Sleep Diseases and Disorders
Notice NOT-HL-18-660 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 23, 2018 Category: Research Source Type: funding
Request for Information (RFI): Soliciting Input for future research at the National Heart, Lung, and Blood Institute on Factor VIII (FVIII) immunogenicity and FVIII inhibitor prevention/eradication in patients with Hemophilia A
Notice NOT-HL-18-652 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 5, 2018 Category: Research Source Type: funding
NHLBI Interest in Administrative Supplements to Enhance HIV-related Heart, Lung, Blood, and Sleep Research
Notice NOT-HL-18-648 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 28, 2018 Category: Research Source Type: funding
Notice to Extend the Expiration Date for PAR-16-021 "NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)"
Notice NOT-HL-18-645 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 21, 2018 Category: Research Source Type: funding
